Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | FLT3 |
| Variant | K663R |
| Impact List | missense |
| Protein Effect | unknown |
| Gene Variant Descriptions | FLT3 K663R lies within the protein kinase domain of the Flt3 protein (UniProt.org). K663R has been identified in the scientific literature (PMID: 39080258, PMID: 40196870), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Sep 2025). |
| Associated Drug Resistance | |
| Category Variants Paths |
FLT3 mutant FLT3 exon16 FLT3 K663R |
| Transcript | NM_004119.3 |
| gDNA | chr13:g.28028243T>C |
| cDNA | c.1988A>G |
| Protein | p.K663R |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_004119.3 | chr13:g.28028243T>C | c.1988A>G | p.K663R | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 K663R | hematologic cancer | sensitive | Gilteritinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 K663R in culture (PMID: 40196870). | 40196870 |
| FLT3 K663R | hematologic cancer | sensitive | Quizartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 K663R in culture (PMID: 40196870). | 40196870 |
| FLT3 K663R | hematologic cancer | sensitive | Midostaurin | Preclinical - Cell culture | Actionable | In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 K663R in culture (PMID: 40196870). | 40196870 |